3 US Penny Stocks With Market Caps Up To 400M
NAUT Stock | USD 2.24 0.06 2.61% |
Slightly above 59% of Nautilus Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that many traders are alarmed. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
Nautilus |
As the U.S. stock market reaches record highs following Donald Trumps election victory, investors are keenly observing how different sectors and asset classes will perform under the new administration. Amidst this backdrop, penny stocksoften representing smaller or newer companiesremain a point of interest for those seeking unique investment opportunities. Though the term penny stock might sound like a relic of past trading days, these stocks can still offer significant growth potential...
Read at finance.yahoo.com
Nautilus Biotechnology Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Nautilus Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Nautilus Biotechnology Fundamental Analysis
We analyze Nautilus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nautilus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nautilus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Nautilus Biotechnology is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Nautilus Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nautilus Biotechnology stock to make a market-neutral strategy. Peer analysis of Nautilus Biotechnology could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics with similar companies.
Peers
Nautilus Biotechnology Related Equities
CCCC | C4 Therapeutics | 8.59 | ||||
IPSC | Century Therapeutics | 5.52 | ||||
CSBR | Champions Oncology | 4.87 | ||||
MNOV | MediciNova | 2.99 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
DTIL | Precision BioSciences | 2.53 | ||||
BCAB | Bioatla | 2.44 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
RZLT | Rezolute | 1.00 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
BEAM | Beam Therapeutics | 0.63 | ||||
KYMR | Kymera Therapeutics | 0.02 | ||||
MOLN | Molecular Partners | 0.17 | ||||
CRBU | Caribou Biosciences | 0.45 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
HCWB | HCW Biologics | 6.00 |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.